Abnormal Cervical Screening Management (ASCCP 2019) — free guideline decision tool
Translate an abnormal cervical screening result into the ASCCP 2019 risk-based management direction and clinical action threshold. Instant, browser-side.
Open guideline tool →Guideline-based
Implements the decision logic from published clinical guidelines.
Runs in your browser
No installation. Enter the patient's values and get a guideline recommendation instantly.
Data stays local
Nothing is uploaded. Results are for licensed clinicians only.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Current screening result (HPV triage / co-test) | HPV+ ASC-US or LSIL |
|---|
→ManagementColposcopy/biopsy
- Current result：Immediate CIN3+ ~ 4% (reaches colposcopy threshold)
- Management direction：Colposcopy/biopsy (HPV+ ASC-US and LSIL carry similar risk and are managed the same)
- Clinical action threshold：Immediate CIN3+: ≥ 60% favour expedited treatment / 25–< 60% treatment or colposcopy either / 4–< 25% colposcopy / < 4% with 5-year ≥ 0.55% repeat at 1 year / 5-year 0.15–< 0.55% repeat at 3 years / < 0.15% return to routine screening
| Current screening result (HPV triage / co-test) | HPV− and cytology NILM |
|---|
→ManagementReturn to routine screening
- Current result：Immediate CIN3+ risk very low
- Management direction：Return to routine screening (generally 5-yearly co-test or per protocol)
- Clinical action threshold：Immediate CIN3+: ≥ 60% favour expedited treatment / 25–< 60% treatment or colposcopy either / 4–< 25% colposcopy / < 4% with 5-year ≥ 0.55% repeat at 1 year / 5-year 0.15–< 0.55% repeat at 3 years / < 0.15% return to routine screening
Common questions
What is Abnormal Cervical Screening Management (ASCCP 2019)?
Translate an abnormal cervical screening result into the ASCCP 2019 risk-based management direction and clinical action threshold. Instant, browser-side.
How is Abnormal Cervical Screening Management (ASCCP 2019) calculated? What is the core formula?
Clinical action by immediate CIN3+ risk: ≥ 60% expedited treatment; 25–< 60% treatment or colposcopy; 4–< 25% colposcopy; < 4% set 1- or 3-year repeat or return to routine by 5-year risk.
When is Abnormal Cervical Screening Management (ASCCP 2019) used?
Risk-based management direction for abnormal cervical cancer screening (HPV/co-test) under ASCCP 2019.
What are the key clinical points for Abnormal Cervical Screening Management (ASCCP 2019)?
ASCCP 2019 shifted from result-based algorithms to 'equal management for equal risk' using immediate and 5-year CIN3+ risk. The precise risk depends on the current result combined with prior screening history — use the official ASCCP risk-estimator table/App for exact figures. HPV+ HSIL reaches a high immediate risk and favours expedited (excisional) treatment without colposcopy in non-pregnant adults. HPV+ AGC needs colposcopy + endocervical curettage, with endometrial sampling if ≥ 35 years or abnormal bleeding.
What are the limits and cautions when using Abnormal Cervical Screening Management (ASCCP 2019)?
For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
Does Abnormal Cervical Screening Management (ASCCP 2019) upload patient data? Where is it calculated?
Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
How is Abnormal Cervical Screening Management (ASCCP 2019) calculated in practice? Can you show a worked example?
Inputs: Current screening result (HPV triage / co-test) HPV+ ASC-US or LSIL → Result: Management Colposcopy/biopsy（Current result: Immediate CIN3+ ~ 4% (reaches colposcopy threshold), Management direction: Colposcopy/biopsy (HPV+ ASC-US and LSIL carry similar risk and are managed the same), Clinical action threshold: Immediate CIN3+: ≥ 60% favour expedited treatment / 25–< 60% treatment or colposcopy either / 4–< 25% colposcopy / < 4% with 5-year ≥ 0.55% repeat at 1 year / 5-year 0.15–< 0.55% repeat at 3 years / < 0.15% return to routine screening） Inputs: Current screening result (HPV triage / co-test) HPV− and cytology NILM → Result: Management Return to routine screening（Current result: Immediate CIN3+ risk very low, Management direction: Return to routine screening (generally 5-yearly co-test or per protocol), Clinical action threshold: Immediate CIN3+: ≥ 60% favour expedited treatment / 25–< 60% treatment or colposcopy either / 4–< 25% colposcopy / < 4% with 5-year ≥ 0.55% repeat at 1 year / 5-year 0.15–< 0.55% repeat at 3 years / < 0.15% return to routine screening）
Run Abnormal Cervical Screening Management (ASCCP 2019) now
Translate an abnormal cervical screening result into the ASCCP 2019 risk-based management direction and clinical action threshold. Instant, browser-side.
Open guideline tool →For licensed clinicians. Not a substitute for clinical judgement.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.